Literature DB >> 21748630

Therapeutic oligonucleotides.

John Goodchild1.   

Abstract

A brief historical introduction describes early attempts to silence specific genes using the antisense oligonucleotides that flourished in the 1980s. Early aspirations for therapeutic applications were almost extinguished by the unexpected complexity of oligonucleotide pharmacology. Once the biochemistry and molecular biology behind some of the pharmacology was worked out, new approaches became apparent for using oligonucleotides to treat disease. The biochemistry of small nucleic acids is outlined in Section 2. Various approaches employing oligonucleotides to control cellular functions are reviewed in Section 3. These include antisense oligonucleotides and siRNA that bind to RNA, antigene oligonucleotides that bind to DNA, and aptamers, decoys, and CpG oligonucleotides that bind to proteins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21748630     DOI: 10.1007/978-1-61779-188-8_1

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  17 in total

1.  Intracellular Monitoring of AS1411 Aptamer by Time-Resolved Microspectrofluorimetry and Fluorescence Imaging.

Authors:  Eva Kočišová; Petr Praus; Jiří Bok; Stéphanie Bonneau; Franck Sureau
Journal:  J Fluoresc       Date:  2015-07-16       Impact factor: 2.217

2.  End-to-end conformational communication through a synthetic purinergic receptor by ligand-induced helicity switching.

Authors:  Robert A Brown; Vincent Diemer; Simon J Webb; Jonathan Clayden
Journal:  Nat Chem       Date:  2013-09-15       Impact factor: 24.427

3.  Protein Kinase C-α is a Critical Protein for Antisense Oligonucleotide-mediated Silencing in Mammalian Cells.

Authors:  Daniela Castanotto; Min Lin; Claudia Kowolik; Troels Koch; Bo Rode Hansen; Henrik Oerum; Cy A Stein
Journal:  Mol Ther       Date:  2016-03-10       Impact factor: 11.454

4.  The significance of TNFAIP8 in prostate cancer response to radiation and docetaxel and disease recurrence.

Authors:  Chuanbo Zhang; Bhaskar V Kallakury; Jeffrey S Ross; Rajshree R Mewani; Christine E Sheehan; Isamu Sakabe; George Luta; Deepak Kumar; Sivaramakrishna Yadavalli; Joshua Starr; Taduru L Sreenath; Shiv Srivastava; Harvey B Pollard; Ofer Eidelman; Meera Srivastava; Usha N Kasid
Journal:  Int J Cancer       Date:  2013-01-10       Impact factor: 7.396

Review 5.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides.

Authors:  Ryszard Kole; Adrian R Krainer; Sidney Altman
Journal:  Nat Rev Drug Discov       Date:  2012-01-20       Impact factor: 84.694

6.  A molecular nanodevice for targeted degradation of mRNA during protein synthesis.

Authors:  Kyung-Ho Lee; Seung-Eui Min; Haseong Kim; Seung-Goo Lee; Dong-Myung Kim
Journal:  Sci Rep       Date:  2016-02-09       Impact factor: 4.379

Review 7.  Role of long non-coding RNAs in glucose metabolism in cancer.

Authors:  Chunmei Fan; Yanyan Tang; Jinpeng Wang; Fang Xiong; Can Guo; Yumin Wang; Shanshan Zhang; Zhaojian Gong; Fang Wei; Liting Yang; Yi He; Ming Zhou; Xiaoling Li; Guiyuan Li; Wei Xiong; Zhaoyang Zeng
Journal:  Mol Cancer       Date:  2017-07-24       Impact factor: 27.401

8.  Oligonucleotide delivery to the lung: waiting to inhale.

Authors:  Jørgen Kjems; Kenneth A Howard
Journal:  Mol Ther Nucleic Acids       Date:  2012-01-24       Impact factor: 10.183

9.  Nanocarrier-mediated targeting of tumor and tumor vascular cells improves uptake and penetration of drugs into neuroblastoma.

Authors:  Fabio Pastorino; Chiara Brignole; Monica Loi; Daniela Di Paolo; Annarita Di Fiore; Patrizia Perri; Gabriella Pagnan; Mirco Ponzoni
Journal:  Front Oncol       Date:  2013-08-05       Impact factor: 6.244

Review 10.  Oligonucleotides targeting coagulation factor mRNAs: use in thrombosis and hemophilia research and therapy.

Authors:  Marco Heestermans; Bart J M van Vlijmen
Journal:  Thromb J       Date:  2017-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.